NWSA
71
2
WAT
64
4
AIV
60
-14
CI
66
-3
BLK
61
3
GS
80
8
NWL
41
-2
NSC
51
3
PLD
56
-2
MO
65
2
SYY
56
3
NEE
62
-5
DTE
50
-6
LLY
64
-4
CAT
72
2
FDX
62
4
BXP
57
2
GM
80
-2
CMI
71
2
AES
69
-10
NWSA
71
2
WAT
64
4
AIV
60
-14
CI
66
-3
BLK
61
3
GS
80
8
NWL
41
-2
NSC
51
3
PLD
56
-2
MO
65
2
SYY
56
3
NEE
62
-5
DTE
50
-6
LLY
64
-4
CAT
72
2
FDX
62
4
BXP
57
2
GM
80
-2
CMI
71
2
AES
69
-10
Financhill
Back

Avalo Therapeutics 10K Form

Sell
16

AVTX
Avalo Therapeutics

Last Price:
10.82
Seasonality Move:
-8.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AVTX News And Ratings

See the #1 stock for the next 7 days that we like better than AVTX

AVTX Financial Statistics

Sales & Book Value

Annual Sales: $1.92M
Cash Flow: $-2.77M
Price / Cash Flow: 0
Annual Sales: $9.11
Price / Book: 1.54

Profitability

EPS (TTM): -382.18780
Net Income (TTM): $-31.54M
Gross Margin: $640K
Return on Equity: 0%
Return on Assets: -109.45%

Avalo Therapeutics Earnings Forecast

Key Avalo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 9 years for AVTX is 33.26%.
  • The Selling, General & Administrative Expenses for AVTX have been equal to 535.34% of Gross Profit Margin.
  • The Research & Development expenses have been 716.42% of Revenue.
  • The Interest Expense is -10.83% of Operating Income.
  • The Net Earning history of AVTX is -1,639.50% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Avalo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Current Symbol: AVTX
Website: avalotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.82
Quick Ratio: 1.64

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AVTX Technical Analysis vs Fundamental Analysis

Sell
16
Avalo Therapeutics (AVTX) is a Sell

Is Avalo Therapeutics a Buy or a Sell?